These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27484791)

  • 1. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
    Bresler SC; Min L; Rodig SJ; Walls AC; Xu S; Geng S; Hodi FS; Murphy GF; Lian CG
    Lab Invest; 2017 Feb; 97(2):207-216. PubMed ID: 27918555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
    Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
    J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
    Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
    Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune-active tumor microenvironment favors clinical response to ipilimumab.
    Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
    Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
    Van Allen EM; Miao D; Schilling B; Shukla SA; Blank C; Zimmer L; Sucker A; Hillen U; Foppen MHG; Goldinger SM; Utikal J; Hassel JC; Weide B; Kaehler KC; Loquai C; Mohr P; Gutzmer R; Dummer R; Gabriel S; Wu CJ; Schadendorf D; Garraway LA
    Science; 2015 Oct; 350(6257):207-211. PubMed ID: 26359337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
    Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
    Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications.
    Dai J; Jia J; Zhang F; Liu K; Xi Y; Yuan P; Mao L; Bai X; Wei X; Wang B; Li J; Xu Y; Liu T; Chang S; Shao Y; Guo J; Ying J; Si L
    Cancer Res Commun; 2024 May; 4(5):1351-1362. PubMed ID: 38695555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
    Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
    Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
    Romano E; Kusio-Kobialka M; Foukas PG; Baumgaertner P; Meyer C; Ballabeni P; Michielin O; Weide B; Romero P; Speiser DE
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6140-5. PubMed ID: 25918390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma: tumor microenvironment and new treatments.
    Giavina-Bianchi MH; Giavina-Bianchi PF; Festa C
    An Bras Dermatol; 2017; 92(2):156-166. PubMed ID: 28538872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.
    Schartz NE; Farges C; Madelaine I; Bruzzoni H; Calvo F; Hoos A; Lebbé C
    Melanoma Res; 2010 Jun; 20(3):247-50. PubMed ID: 20216240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.